Literature DB >> 25151961

Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.

M H Lopes1, T G Santos2, B R Rodrigues2, N Queiroz-Hazarbassanov2, I W Cunha3, A P Wasilewska-Sampaio2, B Costa-Silva2, F A Marchi4, L F Bleggi-Torres5, P I Sanematsu6, S H Suzuki6, S M Oba-Shinjo7, S K N Marie7, E Toulmin8, A F Hill8, V R Martins9.   

Abstract

Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrP(C)) triggers a large number of trophic effects in the nervous system. We found that both PrP(C) and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrP(C) and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrP(C) binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrP(C) binding site (HOP230-245) abrogates this effect. PrP(C) knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrP(C)-HOP engagement is a promising approach for GBM therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25151961     DOI: 10.1038/onc.2014.261

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurosci       Date:  2011-08-03       Impact factor: 34.870

2.  A comparison between manual and automated evaluations of tissue microarray patterns of protein expression.

Authors:  Arthur W Alvarenga; Claudia M Coutinho-Camillo; Bruna R Rodrigues; Rafael M Rocha; Luiz Fernando B Torres; Vilma R Martins; Isabela W da Cunha; Glaucia N M Hajj
Journal:  J Histochem Cytochem       Date:  2013-01-21       Impact factor: 2.479

3.  C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances.

Authors:  P Muller; E Ruckova; P Halada; P J Coates; R Hrstka; D P Lane; B Vojtesek
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

4.  Pro-prion binds filamin A, facilitating its interaction with integrin beta1, and contributes to melanomagenesis.

Authors:  Chaoyang Li; Shuiliang Yu; Fumihiko Nakamura; Olli T Pentikäinen; Neena Singh; Shaoman Yin; Wei Xin; Man-Sun Sy
Journal:  J Biol Chem       Date:  2010-07-21       Impact factor: 5.157

5.  Prion protein expression and the M129V polymorphism of the PRNP gene in patients with colorectal cancer.

Authors:  Anna G Antonacopoulou; Maria Palli; Stella Marousi; Fotinos-Ioannis Dimitrakopoulos; Urania Kyriakopoulou; Athanasios C Tsamandas; Chrisoula D Scopa; Athanasios G Papavassiliou; Haralabos P Kalofonos
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

6.  Silencing of cellular prion protein (PrPC) expression by DNA-antisense oligonucleotides induces autophagy-dependent cell death in glioma cells.

Authors:  Giulia Barbieri; Silvia Palumbo; Konrad Gabrusiewicz; Alberto Azzalin; Nicoletta Marchesi; Alessandro Spedito; Marco Biggiogera; Elena Sbalchiero; Giuliano Mazzini; Clelia Miracco; Luigi Pirtoli; Bozena Kaminska; Sergio Comincini
Journal:  Autophagy       Date:  2011-08-01       Impact factor: 16.016

7.  POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?

Authors:  Anna G Antonacopoulou; Petros D Grivas; Lambros Skarlas; Melpomeni Kalofonos; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

8.  Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent.

Authors:  Tomohisa Horibe; Masayuki Kohno; Mari Haramoto; Koji Ohara; Koji Kawakami
Journal:  J Transl Med       Date:  2011-01-14       Impact factor: 5.531

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  23 in total

1.  Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis.

Authors:  J H Lee; Y-S Han; Y M Yoon; C W Yun; S P Yun; S M Kim; H Y Kwon; D Jeong; M J Baek; H J Lee; S-J Lee; H J Han; S H Lee
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

2.  Prion Protein Expression is Correlated with Glioma Grades.

Authors:  Qiaoli Luo; Yisong Wang; Dongying Fan; Shijie Wang; Peigang Wang; Jing An
Journal:  Virol Sin       Date:  2020-03-31       Impact factor: 4.327

Review 3.  Targeting prion protein interactions in cancer.

Authors:  Tiago G Santos; Marilene H Lopes; Vilma R Martins
Journal:  Prion       Date:  2015       Impact factor: 3.931

Review 4.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

Review 5.  Unconventional Protein Secretion in Brain Tumors Biology: Enlightening the Mechanisms for Tumor Survival and Progression.

Authors:  Rebeca Piatniczka Iglesia; Mariana Brandão Prado; Rodrigo Nunes Alves; Maria Isabel Melo Escobar; Camila Felix de Lima Fernandes; Ailine Cibele Dos Santos Fortes; Maria Clara da Silva Souza; Jacqueline Marcia Boccacino; Giovanni Cangiano; Samuel Ribeiro Soares; João Pedro Alves de Araújo; Deanna Marie Tiek; Anshika Goenka; Xiao Song; Jack Ryan Keady; Bo Hu; Shi Yuan Cheng; Marilene Hohmuth Lopes
Journal:  Front Cell Dev Biol       Date:  2022-06-15

6.  High Expression of PRNP Predicts Poor Prognosis in Korean Patients with Gastric Cancer.

Authors:  Minseok Choi; SeongRyeol Moon; Hyo Jin Eom; Seung Mook Lim; Yon Hui Kim; Seungyoon Nam
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

7.  PRNP/prion protein regulates the secretion of exosomes modulating CAV1/caveolin-1-suppressed autophagy.

Authors:  Marcos V S Dias; Bianca L Teixeira; Bruna R Rodrigues; Rita Sinigaglia-Coimbra; Isabel Porto-Carreiro; Martín Roffé; Glaucia N M Hajj; Vilma R Martins
Journal:  Autophagy       Date:  2016-09-14       Impact factor: 16.016

8.  Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells.

Authors:  Tonielli Cristina Sousa de Lacerda; Bruno Costa-Silva; Fernanda Salgueiredo Giudice; Marcos Vinicios Salles Dias; Gabriela Pintar de Oliveira; Bianca Luise Teixeira; Tiago Goss Dos Santos; Vilma Regina Martins
Journal:  Clin Exp Metastasis       Date:  2016-04-25       Impact factor: 5.150

9.  MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression.

Authors:  G S Kinker; L H Ostrowski; P A C Ribeiro; R Chanoch; S M Muxel; I Tirosh; G Spadoni; S Rivara; V R Martins; T G Santos; R P Markus; P A C M Fernandes
Journal:  J Mol Med (Berl)       Date:  2021-01-03       Impact factor: 4.599

Review 10.  The Cellular Prion Protein: A Player in Immunological Quiescence.

Authors:  Maren K Bakkebø; Sophie Mouillet-Richard; Arild Espenes; Wilfred Goldmann; Jörg Tatzelt; Michael A Tranulis
Journal:  Front Immunol       Date:  2015-09-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.